Compare · HAE vs INBS
HAE vs INBS
Side-by-side comparison of Haemonetics Corporation (HAE) and Intelligent Bio Solutions Inc. (INBS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAE and INBS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- HAE is the larger of the two at $5.60B, about 959.0x INBS ($5.8M).
- HAE has been more active in the news (9 items in the past 4 weeks vs 7 for INBS).
- HAE has more recent analyst coverage (25 ratings vs 0 for INBS).
- Company
- Haemonetics Corporation
- Intelligent Bio Solutions Inc.
- Price
- -
- -
- Market cap
- $5.60B
- $5.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1991
- 2020
- News (4w)
- 9
- 7
- Recent ratings
- 25
- 0
Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Latest HAE
- VP, Chief Accounting Officer Maunsell Farris Maryanne exercised 2,146 shares at a strike of $87.33, covered exercise/tax liability with 1,724 shares and sold $101,148 worth of shares (836 units at $120.99), decreasing direct ownership by 7% to 5,828 units (SEC Form 4) to cover taxes
- Jefferies initiated coverage on Haemonetics with a new price target
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form 10-Q filed by Haemonetics Corporation
- Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
- EVP, Chief Commercial Officer Galvin Roy covered exercise/tax liability with 146 shares, decreasing direct ownership by 0.37% to 39,805 units (SEC Form 4) to cover withholding tax
- Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line
- Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
- SEC Form 8-K filed by Haemonetics Corporation
Latest INBS
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Intelligent Bio Solutions Inc.
- Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth
- Intelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12
- SEC Form DEF 14A filed by Intelligent Bio Solutions Inc.
- SEC Form PRE 14A filed by Intelligent Bio Solutions Inc.
- Amendment: SEC Form 10-K/A filed by Intelligent Bio Solutions Inc.
- SEC Form 8-K filed by Intelligent Bio Solutions Inc.
- SEC Form EFFECT filed by Intelligent Bio Solutions Inc.
- SEC Form 424B3 filed by Intelligent Bio Solutions Inc.